CClinicalTrials.gg
Not yet recruitingNCT06117215Sd-PremensUpdated Nov 3, 2023

Prevalence of Premenstrual Syndrome in Women of Reproductive Age

An observational study in Premenstrual Syndrome, sponsored by Université de Reims Champagne-Ardenne. Not yet recruiting at 1 site in France. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-03.

Sponsored by Université de Reims Champagne-Ardenne · Observational

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 8 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
2,000
Ages
18 Years and older
Sex
Female
01

Study summary

The menstrual cycle is a recurring process in the lives of women from puberty until menopause. This cycle can cause various discomforts, including premenstrual syndrome.

Described differently, premenstrual syndrome is a collection of physical and psychological symptoms that occur during the luteal phase of the menstrual cycle and subside upon the arrival of menstruation. This definition is conditioned by the existence of a free interval of at least one week between the end of the period and the appearance of these symptoms, as well as a global impairment of functioning and quality of life for women.

The impact on the personal, social, and professional lives of affected women, as well as the pain and discomfort it causes, may be perceived as insignificant or normal by women. Therefore, few women report the existence of these disorders to healthcare professionals. As the subject is not approached, these women are not taken care of even though therapeutic solutions could be proposed.

This pathology affects a large number of women, but its prevalence differs greatly depending on the studies conducted on the subject, suggesting a lack of knowledge of this syndrome.

Read the detailed description

The main aim is to describe the prevalence of premenstrual syndrome among women of reproductive age.

02

Conditions studied

  • Premenstrual Syndrome

Keywords

  • Premenstrual syndrome
  • women reproductive age
  • prevalence
03

In context

Syndrome

9,217 studies on the registry are indexed under Syndrome; 1,031 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 102 across 2,209 observational studies indexed under Syndrome.

Browse Syndrome studies →

Lead sponsor

Université de Reims Champagne-Ardenne is the lead sponsor of 62 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

women of chilbearing age

Inclusion criteria

  • women in childbearing age, i.e., menstrual or secondary amenorrhoea, non-menopausal
  • Over 18 years of age
  • Agreeing to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Menopause
  • Having had a hysterectomy
  • With primary amenorrhea
  • Protected by law
  • Refusing to participate in the study
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • women of reproductive age

    women of reproductive age

    Other: Data collection

Interventions

  • OtherData collection

    data collection

06

What researchers measure

Primary outcomes

  1. premenstrual syndrome

    Prevalence of premenstrual syndrome defined as a set of physical, psychic and behavioral symptoms, appearing in the luteal phase of the menstrual cycle (that is, in the days before menstruation) and yielding with them, conditioned by a sufficient severity to alter the overall functioning and quality of life of women and must be present over at least 2 consecutive cycles.

    Time frame: Day 0

07

Study locations

1 site
  • Ufr Medecine Urca
    Reims, 51100, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06117215
Lead sponsor
Université de Reims Champagne-Ardenne
Responsible party
Sponsor
First posted
Nov 3, 2023
Start date
Dec 1, 2023 (estimated)
Primary completion
Feb 1, 2024 (estimated)
Completion
May 1, 2024 (estimated)
Last update
Nov 3, 2023

Study contacts

Barbe Coralie
Contact
coralie.barbe@univ-reims.fr
0326913665 ext. +33
CURRS CURRS
Contact
curss@univ-reims.fr
0326918822 ext. +33
Kristner Pauline, Dr
principal investigator · CH Épernay

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion